NAPLES, Fla., Sept. 20, 2021 /PRNewswire/ -- Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),
a biotechnology company developing a next-generation mental health
and oncology treatment clinical discovery platform for the mind and
body using psychedelics and cannabinoids, today announced that Dr.
Joseph Tucker, Chief Executive
Officer of Enveric Biosciences, will participate in two upcoming
investor conferences:
Maxim's Advances in Mental Health Virtual Conference
Wednesday, September 22nd
at 10:00 a.m. ET
Panel titled: Next Gen Psychedelics: Novel Chemical
Entities
To attend, register here
Benzinga's Healthcare Small Cap Virtual Conference
Thursday, September 30th
at 3:40 p.m. ET
To attend, register here
For more information about the conferences, or to schedule a
one-on-one meeting with Enveric's management, please contact your
appropriate representative directly, or send an email to Maxim at
jthompson@maximgrp.com, Benzinga at VIPevents@benzinga.com, or KCSA
Strategic Communications at EnvericBio@kcsa.com.
About Enveric Biosciences
Enveric Biosciences (NASDAQ:
ENVB) is an innovative biotechnology company developing a
next-generation mental health and oncology treatment clinical
discovery platform, leveraging psychedelic-derived molecules for
the mind and synthetic cannabinoids for the body. Enveric's robust
pipeline supports drug development from the clinic to
commercialization for millions of patients in need around the world
suffering from conditions that include cancer-related distress,
PTSD and more. For more information, please visit
www.enveric.com.
Investor Contacts
Valter
Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Media Contacts
Caitlin
Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 212.896.1204
ckasunich@kcsa.com / rcona@kcsa.com
View original
content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-september-2021-301380168.html
SOURCE Enveric Biosciences